Streetbeat News

Analyst Ratings

TVTX

Travere Therapeutics shares rose following an upgrade from Guggenheim, which changed its rating from Neutral to Buy and set a $25 price target.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 3:35 pm

CLDX

Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Celldex Therapeutics (NASDAQ:CLDX) and maintained a price target of $67.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 3:34 pm

BMRN

Cantor Fitzgerald has reiterated its Overweight rating on Biomarin Pharmaceutical, maintaining a price target of $110.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 3:32 pm

ENTG

Entegris (NYSE:ENTG) has seen a 14.37% decrease in its short percent of float, now at 2.74%. This is lower than its peers' average of 5.47%. The reduced short interest may indicate a more bullish sentiment towards the stock.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 3:30 pm

GWRE

Citigroup analyst Tyler Radke maintains a Neutral rating on Guidewire Software (NYSE:GWRE) but raises the price target from $123 to $165.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 3:29 pm

BIIB

Cantor Fitzgerald analyst Eric Schmidt has reiterated an Overweight rating on Biogen (NASDAQ:BIIB) and maintained a price target of $292.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 3:28 pm

DOOO

Citigroup analyst James Hardiman maintains a Buy rating on BRP (NASDAQ:DOOO) but lowers the price target from $80 to $75.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 3:26 pm

SMMT

Citigroup analyst Yigal Nochomovitz maintains a Buy rating on Summit Therapeutics and raises the price target from $13 to $19.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 3:25 pm

BBIO

Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on BridgeBio Pharma (NASDAQ:BBIO) and maintained a $70 price target.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 3:24 pm

AXSM

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a price target of $107.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 3:21 pm